Evidence map›Paper›PMID 38672168›Full record

ReviewBiomedicines2024

Novel Biomaterials in Glaucoma Treatment.

Adéla Klézlová, Petr Bulíř, Andrea Klápšťová, Magdaléna Netuková, Kateřina Šenková, Jana Horáková, Pavel Studený

Open access · goldAbstract readReview
In one paragraph

Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Adéla KlézlováOphthalmology Department, Third Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Ruská 87, Praha 10, 100 00 Prague, Czech Republic.
Petr BulířOphthalmology Department, Third Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Ruská 87, Praha 10, 100 00 Prague, Czech Republic.
Andrea KlápšťováDepartment of Nonwovens and Nanofibrous Materials, Faculty of Textile Engineering, Technical University of Liberec, 461 17 Liberec, Czech Republic.
Magdaléna NetukováOphthalmology Department, Third Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Ruská 87, Praha 10, 100 00 Prague, Czech Republic.
Kateřina ŠenkováOphthalmology Department, Third Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Ruská 87, Praha 10, 100 00 Prague, Czech Republic.
Jana HorákováDepartment of Nonwovens and Nanofibrous Materials, Faculty of Textile Engineering, Technical University of Liberec, 461 17 Liberec, Czech Republic.ORCID 0000-0003-2926-0570
Pavel StudenýOphthalmology Department, Third Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Ruská 87, Praha 10, 100 00 Prague, Czech Republic.
Charles University · CZTechnical University of Liberec · CZ

Funding

Agentura Pro Zdravotnický Výzkum České Republiky NU 23-08-00586
6 · The paper itself

Abstract

Glaucoma is a significant cause of blindness worldwide, and its treatment remains challenging. The disease progressively leads to damage to the optic disc and thus loss of visual acuity and visual field. High intraocular pressure (IOP) is a common risk factor. There are three major methods to treat this disease: topical, laser, and surgical. None of these are completely satisfactory; therefore, alternatives using new biomaterials are being sought. Since biomaterial engineering has experienced significant growth in recent decades, its products are gradually being introduced to various branches of medicine, with the exception of ophthalmology. Biomaterials, such as glaucoma drainage implants, have been successfully used to treat glaucoma. There is significant ongoing research on biomaterials as drug delivery systems that could overcome the disadvantages of topical glaucoma treatment, such as poor intraocular penetration or frequent drug administration. This article summarizes the use of novel biomaterials for glaucoma treatment presented in the literature. The literature search was based on articles published in English on PubMed.gov, Cochranelibrary.com, and Scopus.com between 2018 and 2023 using the following term "biomaterials in glaucoma." A total of 103 published articles, including twenty-two reviews, were included. Fifty-nine articles were excluded on the basis of their titles and abstracts.

Indexed as

biomaterialsdrug delivery systemsglaucomaglaucoma drainage implants

Identifiers

PMID38672168
PMCPMC11048501
OpenAlexW4394565757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.